

### 2016 Annual Results

February 10th, 2017

#### Mr. Christian Mulliez

Chief Financial Officer

ĽORÉAL



# 2016 consolidated group sales (in million euros)

Growth at constant exchange rates	+5.1%
Of which:	
– like-for-like growth	+4.7%
<ul> <li>external growth impact</li> </ul>	+0.4%
Exchange rate impact	-2.8%
Reported growth	+2.3%



### Changes in exchange rates (against the euro)

	Weight in 2016 consolidated sales	Average rate 2015	Average rate 2016	Change 2016 / 2015
Euro	24.7%	—	_	—
US Dollar (€1=)	27.3%	1.109	1.106	+0.3%
Chinese Yuan	7.7%	0.143	0.136	-5.2%
Sterling Pound	6.4%	1.378	1.225	-11.1%
Brazilian Real	2.9%	0.275	0.261	-5.1%
Canadian Dollar	2.8%	0.706	0.682	-3.4%
Russian Ruble	2.3%	0.015	0.014	-8.8%
Japanese Yen (1000)	1.9%	7.450	8.329	+11.8%
Mexican Peso	1.5%	0.057	0.048	-14.9%



			% change		
	<b>2015</b> (€ million)	<b>2016</b> (€ million)	Like-for-like	At constant exchange rates	Reported
Professional Products	3 400	3 400	+1.8%	+2.0%	+0.0%
Consumer Products	11 844	11 993	+4.4%	+4.6%	+1.3%
L'Oréal Luxe	7 230	7 662	+6.9%	+7.8%	+6.0%
Active Cosmetics	1 816	1 861	+5.7%	+5.4%	+2.4%
Divisions Total	24 290	24 916	+4.9%	+5.2%	+2.6%
The Body Shop	967	921	+0.6%	+0.9%	-4.8%
Consolidated Total	25 257	25 837	+4.7%	+5.1%	+2.3%



			% change		
	<b>2015</b> (€ million)	<b>2016</b> (€ million)	Like-for-like	At constant exchange rates	Reported
Western Europe	7 968	8 008	+2.4%	+2.5%	+0.5%
North America	6 654	7 099	+5.8%	+6.7%	+6.7%
New Markets	9 667	9 809	+6.3%	+6.5%	+1.5%
Total divisions	24 290	24 916	+4.9%	+5.2%	+2.6%

\* As of July 1<sup>st</sup>, 2016, the Asian Travel Retail business of the Consumer Products Division, previously recorded under the Western Europe Zone, was transferred to the Asia, Pacific Zone. 2015 figures have been restated to allow for this change.



#### 2016 total divisions sales New Markets\*

		% change		
	<b>2016</b> (€ million)	Like-for-like	At constant exchange rates	Reported
Asia, Pacific	5 635	+3.6%	+3.6%	+1.8%
Latin America	1 838	+11.1%	+11.9%	-1.8%
Eastern Europe	1 572	+10.4%	+10.4%	+2.7%
Africa, Middle-East	764	+7.9%	+7.9%	+5.0%
Total New Markets	9 809	+6.3%	+6.5%	+1.5%

\* As of July 1<sup>st</sup>, 2016, the Asian Travel Retail business of the Consumer Products Division, previously recorded under the Western Europe Zone, was transferred to the Asia, Pacific Zone. 2015 figures have been restated to allow for this change.



### Consolidated profit and loss accounts: from sales to operating profit

(in million euros)	2015	As a % of sales	2016	As a % of sales	Change
Sales	25 257.4	100.0%	25 837.1	100.0%	+2.3%
Cost of sales	-7 277.4	28.8%	-7 341.7	28.4%	
Gross profit	17 980.0	71.2%	18 495.4	71.6%	+40bp
Research and development	-794.1	3.1%	-849.8	3.3%	
Advertising and promotion	-7 359.6	29.1%	-7 498.7	29.0%	
Selling, general and administrative expenses	-5 438.6	21.5%	-5 607.0	21.7%	
Operating profit	4 387.7	17.4%	4 539.9	17.6%	+20bp



### Operating profit margin by division

(as a % of sales)	2014	2015	2016
Professional Products	20.1%	20.0%	20.3%
Consumer Products	20.3%	20.1%	20.2%
L'Oréal Luxe	20.5%	20.7%	21.2%
Active Cosmetics	22.7%	22.8%	23.2%
Total divisions before non-allocated expenses	20.5%	20.5%	20.7%
Non-allocated expenses*	-2.8%	-2.6%	-2.6%
Total divisions after non-allocated expenses	17.7%	17.8%	18.1%
The Body Shop	7.5%	5.7%	3.7%
Group	17.3%	17.4%	17.6%

\* Central group expenses, fundamental research expenses, stock-options & free grant of shares expenses and miscellaneous items as a % of total divisions sales



(as a % of sales)	2014	2015	2016
Western Europe	22.6%	22.6%	22.9%
North America	18.7%	18.9%	19.6%
New Markets	19.8%	19.9%	19.7%
Total divisions*	20.5%	20.5%	20.7%

\* Before non allocated expenses. As of July 1<sup>st</sup>, 2016, the Asian Travel Retail business of the Consumer Products Division, previously recorded under the Western Europe Zone, was transferred to the Asia, Pacific Zone. 2014 and 2015 figures have been restated to allow for this change.



## Consolidated profit and loss accounts: from operating profit to net profit excluding non-recurring items

(in million euros)	2015	2016	% change 2016 / 2015
Operating profit	4 387.7	4 539.9	+3.5%
Financial revenues-expenses before dividends received	-13.8	-19.3	
Sanofi dividends	336.9	346.5	
Profit before tax and associates, before non-recurring items	4 710.8	4 867.1	+3.3%
Income tax excluding non-recurring items	-1 219.7	-1 216.8	
Share of profit of associates, excluding non-recurring items	-	-0.1	
Non-controlling interests	-1.3	-3.0	
Net profit excluding non-recurring items, after non-controlling interests	3 489.8	3 647.2	
Earnings per share* (in euros)	6.18	6.46	+4.6%
Diluted average number of shares	564 891 388	564 509 135	

\* Diluted earnings per share based on net profit excluding non-recurring items, after non-controlling interests

FAL



# Consolidated profit and loss accounts: from net profit excluding non-recurring items to net profit

(in million euros)	2015	2016	% change
Net profit from continuing operations excluding non-recurring items	3 489.8	3 647.2	+4.5%
Non-recurring items	-192.5	-541.5	
- Of which:			
- other income and expenses	-189.3	-543.7	
<ul> <li>taxes on non-recurring items</li> </ul>	-3.2	+2.2	
Net profit*	3 297.4	3 105.8	

\* After non-controlling interests



#### Cash flow statements


(in million euros)	2015	2016	% change 2016 / 2015
Net profit	3 298.5	3 108.7	
Depreciation, amortisation and provisions	933.8	1 424.5	
Capital gains and losses on disposals of assets, changes in deferred taxes and others	+171.2	+184.0	
Share of profit of associates, net of dividends received	-4.0	+0.1	
Cash flow	4 399.5	4 717.3	+7.2%
Changes in working capital	-196.4	-12.7	
Investments	-1 172.1	-1 386.5	
Operating net cash flow	3 031.0	3 318.1	+9.5%
Dividends paid	-1 534.8	-1 832.9	
Acquisitions	-435.3	-1 209.3	
Acquisitions of treasury stock	—	-499.1	
Capital increase	+338.6	+163.2	
Others*	-19.5	-14.8	
Residual cash flow after acquisitions	+1 380.0	-74.7	

\* Others include disposal of treasury stock and purchase of non-controlling interests



Balance sheet (in billion euros)

#### Liabilities




Assets

RÉAL



in million euros	31 <sup>st</sup> Dec. 2015	in million euros	31 <sup>st</sup> Dec. 2016
Net cash	618	Net cash	481
Gearing*	N.A.	Gearing*	N.A.

\*Net debt / equity attributable to owners of the company




\* Proposed at the shareholders' meeting to be held on April 20th, 2017


2016 dividend paid in 2017: pay-out of the 10% loyalty bonus (preferential dividend of 10%), for shares held in registered form since 2014

RFAL

10 February 2017







\* Taking into account the Sanofi history with regards to the dividends

\*\* Based on the dividend proposed at the shareholders' meeting to be held on April 20th, 2017

RFAL



#### -----Avertissement / Disclaimer -----

« Ce document ne constitue pas une offre de vente ou la sollicitation d' une offre d' achat de titres L' Oréal. Si vous souhaitez obtenir des informations plus complètes concernant L' Oréal, nous vous invitons à vous reporter aux documents publics déposés en France auprès de l' Autorité des Marchés Financiers (également disponibles en version anglaise sur notre site Internet www.loreal-finance.com).Ce document peut contenir certaines déclarations de nature prévisionnelle. Bien que la Société estime que ces déclarations reposent sur des hypothèses raisonnables à la date de publication du présent communiqué, elles sont par nature soumises à des risques et incertitudes pouvant donner lieu à un écart entre les chiffres réels et ceux indiqués ou induits dans ces déclarations.»

"This document does not constitute an offer to sell, or a solicitation of an offer to buy, L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers (which are also available in English on our Internet site: www.loreal-finance.com). This document may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements."

